Wockhardt is currently trading at Rs 307.30, up by 11.25 points or 3.80% from its previous closing of Rs 296.05 on the BSE.
The scrip opened at Rs 298.40 and has touched a high and low of Rs 308.90 and Rs 296.00 respectively. So far 79641 shares were traded on the counter.
The BSE group 'A' stock of face value Rs 5 has touched a 52 week high of Rs 473.00 on 02-Aug-2011 and a 52 week low of Rs. 251.25 on 06-Jan-2012.
Last one week high and low of the scrip stood at Rs 308.90 and Rs 251.25 respectively. The current market cap of the company is Rs 3276.51 crore.
The promoters holding in the company stood at 73.64% while Institutions and Non-Institutions held 7.82% and 18.15% respectively.
Wockhardt, a pharmaceutical and biotechnology major has received final approval from United States Food and Drug Administration (US FDA) for marketing 50 mcg nasal spray of Fluticasone which is used in treatment of allergic rhinitis. Fluticasone nasal spray is the generic name for the brand Flonase, marketed in the US by Glaxo Smithkline. The company is launching the product immediately.
The total market for this product in the US is about $580 million and there are only three other generic version of the product in the United States. Fluticasone nasal spray is amongst the most widely used corticosteroids in treating allergic rhinitis.
Wockhardt will be manufacturing the nasal spray at its facility in Morton Grove, Illinois, USA. The technology for this nasal spray was developed in-house.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1824.00 |
| Dr. Reddys Lab | 1267.80 |
| Cipla | 1355.80 |
| Zydus Lifesciences | 1074.30 |
| Lupin | 2327.50 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: